“The Chr Hansen Group delivered organic revenue growth of 9% (excluding carmine price effect) in the first half of 2012/13,” said CEO Cees de Jong.
“Preliminary analysis of two clinical studies relating to gastrointestinal health has been finalised.
“Despite indications of positive results, the studies’ primary end points were not met and consequently the data is assessed to be insufficient for approval of an EU health claim.
“Therefore, impairment of capitalised development costs of €8m has been made in Q2.
“Operating profit (EBIT) margin before impairment was at 25.0% at the same level as last year. The company remains committed to achieving improved profit margins through scalability and its outlook for 2012/13 is unchanged.
“We expects organic revenue growth between 8-10% (excluding carmine price effect) and an EBIT margin before special items and impairments above 2011/12.”
Source: Chr Hansen
© FoodBev Media Ltd 2024